other material
confidence high
sentiment positive
materiality 0.75
Delcath's CHOPIN trial published: PHP+immunotherapy shows 54.7% vs 15.8% 1-year PFS
DELCATH SYSTEMS, INC.
- 1-year PFS 54.7% vs 15.8% (adjusted HR 0.34; p=0.0002); median PFS 12.8 vs 8.3 months.
- Median OS 23.1 vs 19.6 months (HR 0.39; p=0.0065); 2-year OS 49.6% vs 22.1%.
- Objective response rate 76.3% vs 39.5%; complete response rate 13% vs 3%.
- Grade ≥3 treatment-related AEs 82% (combo) vs 41% (PHP alone); one treatment-related death in combo arm.